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An Evaluation of Oral Anticoagulation Initiation after an Ischemic Stroke
in Patients with Atrial fibrillation/Atrial Flutter at Hospital Discharge
Jessica Zhao, PharmD; Cody Barfuss, PharmD Candidate; Meri Slavica-Sheley, RPh, PhD, BCPS; Vanessa Jenkins, PharmD; Natalie Swearingen, MSN, RN, CNRN

Background

Discussion

Study Population
• Stroke is the leading cause of permanent disability and decrease in
quality of life.1 More than 795,000 people per year in the US have
stroke, and nearly 87% of those strokes are ischemic.2 In the US,
arrhythmias may be responsible for 10% to 12% of all ischemic
strokes.3
• Previous literature had defined that about 50% of patients
admitted for an ischemic stroke and newly diagnosed with atrial
fibrillation (AF) were not prescribed oral anticoagulation (OAC)
prior to discharge.4 Given these charges, the ASHP Pharmacy
Accountability Measures Work Group is helping to increase
pharmacy accountability through improving quality measures in
antithrombotic safety.5 This study was initiated to provide more
insight on our local OAC prescribing rates prior to or at discharge
and compare it to the data available from literature.
• Pharmacists may be able to make direct impacts on OAC
prescribing for patients through OAC counseling, transition of care
programs, and close pharmacy follow-up after discharge.
• A knowledge gap exists for appropriate timing to prescribe OAC for
patients with AF after ischemic stroke due to the potential risk of
hemorrhagic conversion given the lack of consensus guidelines to
direct therapy. Current recommendations vary between
organizations and some observational data have revealed that
early treatment might be effective and safe.6 Additionally, this
study will identify an area in which pharmacy can play a larger
accountability role to improve outcomes during transitions of care.

Purpose
• To evaluate the use of OAC after an acute ischemic stroke in
patients with AF or atrial flutter and the percentage of
patients with ischemic stroke and documented atrial
flutter/AF who have been prescribed on OAC

Demographic

Female
Age
Race
White or Caucasian
Patient Refused
Asian
American Indian or Alaska Native
Black or African American
Native Hawaiian/Pacific Islander
Creatinine Clearance (n = 159)
> 50 mL/min
30 – 50 mL/min
< 30 mL/min
CHA₂DS₂-VASc Score
Oral Anticoagulation Prior To Admission
None
Apixaban 5 mg
Warfarin
Dabigatran
Apixaban 2.5 mg
Rivaroxaban 20 mg
Rivaroxaban 15mg

Number of Patients (%), n = 159
82 (51.6%)
77.2 ± 10.6
125 (78.6%)
14 (8.8%)
11 (6.9%)
4 (2.5%)
4 (2.5%)
1 (0.6%)
62.4 ± 29.9
99 (63.5%)
41 (26.3%)
16 (10.3%)
5.5

20 (12.6%)
8 (5.0%)
5 (3.1%)
5 (3.1%)
2 (1.3%)

Distribution of Etiology (n = 222)
1%
7%

Distribution of Patients New to OAC vs
Continuing OAC at Discharge (n = 96)

6%

14%

43.8%
56.3%

Cardioembolic
Undetermined etiology
Small vessel occlusion
Large artery atherosclerosis

Distribution of Patients that
Successfully Discharged (n = 159)

Secondary Endpoints

• To evaluate the time frame at which OAC is initiated after an
acute ischemic stroke in the setting of AF or atrial flutter

39.6%

• Retrospective review at a large, tertiary medical center
•Duration: between January 1, 2019 to August 31, 2021

Study Population

• Inclusion Criteria
• Diagnosis of an acute ischemic stroke secondary to AF or
atrial flutter
•18 years of age or older
• Exclusion Criteria
•New onset of stroke while hospitalized
•Pregnancy
•Initial onset of hemorrhagic stroke

New Start

Alive

Deceased

Distribution of Patients that Received
tPA (n = 159)
13.8%

86.2%

No

Yes

Continued OAC

N/A
Dabigatran
Rivaroxaban
Warfarin
Apixaban
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Conclusion

11
15

46
60

Days after Discharge for Number of
Patients Who are New to OAC (n = 42)
8
1
1
2
1
2
2
1
1
1

• The study results reflect previous literature for patients who were
not prescribed OAC at/upon discharge. Antithrombotic safety is an
area identified by the ASHP Pharmacy Work Group in which
pharmacist may significantly impact through discharge counseling,
transitions of care, and outpatient primary care clinic follow-ups.
• Prescribing patterns at this large, tertiary medical center reflected
most updated guideline-directed therapy along with close
outpatient follow-up in the stroke clinic.
• In post ischemic stroke patients secondary to a cardioembolic
etiology, the prescribing pattern was split between initiating OAC
within 3 days or at the 7, 10, or 14 days after an ischemic stroke.

References

22
0

• Previous literature revealed that a 12-day hold in OAC post
ischemic strokes was not associated with increased ischemic
recurrence secondary to AF or atrial flutter.7 This clinical practice is
reflected in the current prescribing pattern at a large, tertiary
medical center.
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Number of Patients

1
2
4
5
6
7
9
18
At discharge
Lost to follow-up
New start inpatient

• Of the 96 patients that were discharged successfully, 42 (43.8%)
were new starts on OAC. The most common newly prescribed OAC
was apixaban (47.9%) followed by warfarin (15.6%). Only 1 (2.4%)
patient was lost to follow-up and could not be accounted for after
the stroke neurologist recommended to start an OAC.

• Some limitations to this study is that retrospective data was
collected from a single-site, thus limiting external validity. Given
the data was collected from a tertiary medical center that is
certified as a Primary Plus Stroke Program, it receives a
disproportionate amount of stroke cases.

Distribution of OAC at/after
Discharge (n = 96)

60.4%

Methods
Study Design

• Of the 159 patients with cardioembolic ischemic strokes, 11 (6.9%)
patients received alteplase (tPA), and 11 (6.9%) received both tPA
and thrombectomy for large vessel occlusion strokes. No
symptomatic bleeding complications occurred in either of the
treatment populations.

Results

Type of OAC

• To evaluate what percentage of patients with ischemic
stroke with documented AF or atrial flutter are prescribed
OAC therapy prior to or at hospital discharge

• Of the included patients, 82 (51.6 %) were females and the
average age was 77.2 years. The most common race was White or
Caucasian (78.6%). The average creatinine clearance was
estimated to be 62 mL/min. A total of 93 (58.5%) patients were
not previously on OAC,, and the most common OAC prior to
admission was apixaban (16.4%) followed by warfarin (12.6%). The
most common reason for not being on OAC was due to high
bleeding risk, followed by non-compliance of OAC.

Days After Discharge

Primary Endpoints

• Out of the 222 patients with a primary diagnosis of an ischemic
stroke, 159 (72%) patients had an ischemic stroke secondary to AF
or atrial flutter. There were 63 patients that did not fit the
inclusion criteria, leaving a total of 159 patients in this
retrospective study. Out of the 159 patients, 96 (60.4%) of the
patients discharged successfully after their admission for an
ischemic stroke.

93 (58.5%)
26 (16.4%)

72%

Outcomes

• AHA/ACC continues to strongly recommend OAC for patients with
atrial flutter or nonvalvular AF to reduce risk of recurrent stroke.
With exceptions, the guidelines do not recommend the
combination of antiplatelets and OAC for secondary prophylaxis of
stroke.6
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